<DOC>
	<DOCNO>NCT00771719</DOCNO>
	<brief_summary>The purpose research study measure level ceftobiprole blood , urine tissue lung administration four dos ceftobiprole . Safety drug also evaluate .</brief_summary>
	<brief_title>Open Label Pharmacokinetic Adult Patients With Ventilator-Associated Pneumonia</brief_title>
	<detailed_description>Patients receive intravenous dose ceftobiprole infuse 4 hour . Multiple blood sample obtain determine concentration Ceftobiprole blood . Bronchoalveolar lavage ( BAL ) sample collect determine concentration ceftobiprole BAL fluid . The penetration drug lung calculate . Four 1000mg administer every 8 hour</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Ceftobiprole</mesh_term>
	<mesh_term>Ceftobiprole medocaril</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<criteria>Informed Consent Between 18 75 year age inclusive VAP 48 hour onset mechanical ventilation BMI 18 35 inclusive Albumin &lt; 3.3 g/dL clinical evidence edema Negative Pregnancy test Expected survival least 7 day Renal impairment ( CrCl &lt; 80 mL/min ) Known drug allergy ( include penicillin , cephalosporin , carbapenems , betalactams ) History seizure Sustained shock , unresponsive sympathomimetics Conditions may jeopardize adherence protocol ( NYHA Class 4 cardiac disease , &gt; 15 % total body burn significant third degree burn )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>VAP</keyword>
</DOC>